
Hagens Berman Sobol Shapiro LLP and Scott+Scott Attorneys at Law LLP Announce a Class Action for All Vaxart Shareholders that May Include You, Even if You Participated in the Previous Partial Settlement with Vaxart
UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
THIS NOTICE PROVIDES ONLY LIMITED INFORMATION ABOUT THE CASE
The Court has certified this lawsuit as a class action for Vaxart shareholders that may include you, even if you participated in the previous partial settlement with Vaxart. This notice summarizes your rights and options, but please visit www.VaxartSecuritiesLitigation.com for more detailed information. If you're included in the Class or Subclass (defined below) and do nothing, you will be bound by whatever results are reached in this class action. However, if you want to be free to bring your own separate suit (at your expense) against the Armistice Defendants (defined below) on the claims at issue, you must submit a 'request for exclusion' by July 25, 2025. There is no money available now, and there may never be any.
Wasn't there a previous settlement? Yes. In 2023, the Court previously approved a partial settlement with Vaxart and certain of its current or former officers and directors. The deadline to collect from or opt out of that settlement has passed. Meanwhile, Plaintiffs continued to litigate claims against the non-settling defendants Armistice Capital, LLC, Armistice Capital Master Fund, Armistice's owner and founder Steven Boyd, and Armistice's managing director Keith Maher (collectively, 'Armistice Defendants'). If Plaintiffs obtain a trial verdict or settlement, you may get a share of the recovery from the Armistice Defendants even if you participated in the previous partial settlement.
What is this case against the Armistice Defendants about? Plaintiffs claim the Armistice Defendants violated Sections 10(b) & 20A of the Securities Exchange Act. The Armistice Defendants deny they did anything wrong. The Court has not decided whether Plaintiffs or the Armistice Defendants are right. Plaintiffs, on behalf of themselves and the Class, will have to prove their claims at a trial beginning on October 27, 2025.
Are you affected? All persons or entities who (i) purchased or otherwise acquired publicly traded Vaxart common stock, or (ii) purchased call options or sold put options thereon, between June 25 and July 24, 2020 inclusive (the 'Class Period'), and were damaged thereby, are members of the Class. Any members of the Class who purchased contemporaneously with the Armistice Defendants' June 26 and 29, 2020 sales of Vaxart common stock and were damaged thereby are also members of the Subclass.
Who represents you? The Court appointed the law firms of Hagens Berman Sobol Shapiro LLP and Scott+Scott Attorneys at Law LLP as 'Class Counsel' to represent you and all Class and Subclass members. You do not have to pay Class Counsel (or anyone else) to have your interests represented in this Action. If a recovery is obtained in this Action, the Court will direct that any attorneys' fees and costs will be paid from any such recovery. However, if instead you submit a 'request for exclusion' (see below), you may hire your own lawyer (at your expense) to bring your own claims against the Armistice Defendants separately.
What are your options? (1) You can either stay in the class action OR (2) you can ask to be excluded.
If you stay in the Class, you will be bound by all Court decisions reached in it, and you won't be able to sue the Armistice Defendants for the same legal claims that are the subject of this lawsuit. To stay in the Class, you don't have to do anything now, and you will be notified later, on how to collect a share of the Class's recovery, if any, that may be obtained.
If you want to be excluded, then you must submit a 'request for exclusion' by July 25, 2025 (see instructions below). If you do, the Court will exclude you from the Class (including the Subclass, if applicable). If you exclude yourself, you cannot get a share of the recovery, if any, obtained in this Action, but you will be free to sue the Armistice Defendants on the same claims (at your own expense) and will not be bound by any orders or judgments entered in this class action.
To exclude yourself, you must send a written request stating that you 'request to be excluded from the Class in In re Vaxart Securities Litigation.' To be valid, your request must also include your name, address, telephone number, your signature, and copies of documents (do not send originals) sufficient to show how many shares of Vaxart common stock (and how many put or call options, if any) you purchased and/or sold between June 25 and July 24, 2020, inclusive. You must submit your exclusion request so that it is received no later than July 25, 2025. There are three ways to submit your exclusion request: (i) mail it to Vaxart Securities Litigation, EXCLUSIONS, c/o A.B. Data, Ltd., P.O. Box 173001, Milwaukee, WI 53217; (ii) submit it on the web portal accessible at www.VaxartSecuritiesLitigation.com; or (iii) email it to exclusion@vaxartsecuritieslitigation.com. Unless otherwise ordered by the Court, your exclusion request must comply with the above requirements to be valid. Please note that you cannot exclude yourself on the phone.
How can you get more information? If you have questions or seek additional information about this action (including the operative Complaint, the Armistice Defendants' Answer, and selected Orders of the Court to date), visit www.VaxartSecuritiesLitigation.com; write to Vaxart Securities Litigation, c/o A.B. Data, Ltd., P.O. Box 173133, Milwaukee, WI 53217; or call 877-388-1723.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
4 days ago
- Business Wire
Principal ® Recommends Shareholders Reject 'Mini-tender' Offer by Potemkin Limited
DES MOINES, Iowa--(BUSINESS WIRE)--Principal Financial Group ® (Nasdaq: PFG) announced today that it has received notice of an unsolicited mini-tender offer by Potemkin Limited ('Potemkin') to purchase up to 100,000 shares of Principal Financial Group, Inc. common stock from Principal ® shareholders. The offer is for approximately 0.0004 percent of Principal's shares of common stock outstanding as of the July 1, 2025, offer date. Potemkin's offer price of $51.70 per share is approximately 34.91 percent lower than the $79.43 closing price of PFG common stock on Nasdaq on June 30, 2025, the last trading day prior to the offer date. Principal does not endorse Potemkin's unsolicited mini-tender offer and recommends that shareholders do not tender their shares in response to Potemkin's offer because the offer is at a price that is significantly below the June 30, 2025, closing common stock price of $79.43 per share. Principal is not associated in any way with Potemkin, its mini-tender offer, or its mini-tender offer documents. Potemkin's offer is generally not subject to the information filing requirements of the Securities Exchange Act and Potemkin is not generally required to file reports, proxy statements and other information with the U.S. Securities and Exchange Commission ('SEC') relating to its business, financial condition and otherwise. Potemkin has made similar mini-tender offers for shares of other companies. Mini-tender offers, such as this one, seek to acquire less than five percent of a company's shares outstanding, thereby avoiding many disclosure and procedural requirements of the SEC. As a result, mini-tender offers do not provide investors with the same level of protections as provided by larger tender offers under U.S. securities laws. The SEC has cautioned investors that some bidders making mini-tender offers at below-market prices are 'hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price.' The SEC's cautionary advice to investors on mini-tender offers is available at Principal urges investors to obtain current market quotations for their shares, consult with their broker or financial advisor, and exercise caution with respect to Potemkin's offer. Principal urges shareholders who have not responded to Potemkin's offer to take no action. Shareholders who have already tendered their shares may withdraw them within 14 days after the date of delivery of the shareholder's Tender Form by providing notice as described in the Potemkin mini-tender offer documents, prior to the expiration of the offer, currently scheduled for Tuesday, September 30, 2025, 5 p.m. Eastern time. Principal encourages shareholders to review carefully the 'Withdrawal Rights' section of the offer documents. Principal encourages brokers and dealers, as well as other market participants, to review the SEC's letter regarding broker-dealer mini-tender offer dissemination and disclosure at and NASD's Notice to Members 9-53, issued July 1999, regarding guidance to members forwarding mini-tender offers to their customers, which can be found at Principal requests that a copy of this news release be included with all distributions of materials relating to Potemkin's mini-tender offer related to shares of Principal Financial Group, Inc. common stock. About Principal Financial Group ® Principal Financial Group ® (Nasdaq: PFG) is a global financial company with approximately 20,000 employees 1 passionate about improving the wealth and well-being of people and businesses. In business for 145 years, we're helping approximately 70 million customers 1 plan, protect, invest, and retire, while working to support the communities where we do business. Principal is proud to be recognized as one of the 2025 World's Most Ethical Companies 2 and named as a 'Best Places to Work in Money Management 3.' Learn more about Principal and our commitment to building a better future at 2 Ethisphere, 2025 3 Pensions & Investments, 2024


Business Wire
08-07-2025
- Business Wire
Allegion Expands Access Solutions Portfolio with Innovative Waitwhile Software Platform
DUBLIN--(BUSINESS WIRE)-- Allegion plc (NYSE: ALLE), a leading global security products and solutions provider, through one of its subsidiaries, has acquired privately owned Waitwhile Inc. (Waitwhile), a leading software-as-a-service provider that specializes in cloud-based appointment scheduling and queue management. Waitwhile's software platform provides virtual wait list and scheduling capabilities that enable businesses to facilitate access to places, services, appointments and events – whether online or in person. Real-time status updates and instant messaging, paired with powerful analytics, improve operational efficiency for both enterprise customers and their end users through reduced wait times and crowd management. Primarily sold in the U.S., Waitwhile has a large footprint of multinational customers who use the platform to power their queue management and appointment experiences globally across healthcare, education, commercial, government and retail markets – supporting more than 300 million end-user visits to date. 'Adding Waitwhile to the Allegion portfolio aligns with our strategy of investing in complementary software products that differentiate our hardware and deliver recurring value to our customers,' Allegion President and CEO John H. Stone said. 'This is an opportunity to deliver value by connecting the virtual queue to secure and seamless physical access at the door in core non-residential markets that we know well. Together, Waitwhile and Allegion can provide the right access to the right people at the right time, all while streamlining operations.' Waitwhile was founded in 2017 by CEO Christoffer Klemming, who is joining Allegion. Klemming will continue leading the Waitwhile business, which has offices in the U.S. and Sweden. 'As market leaders in both digital and physical access, Waitwhile and Allegion are uniquely positioned to shape the future of seamless, in-person customer experiences,' Klemming said. 'Together, we can accelerate innovation and deliver even greater value to the businesses we serve.' Terms of the transaction were not disclosed. About Allegion At Allegion (NYSE: ALLE), we design and manufacture innovative security and access solutions that help keep people safe where they live, learn, work and connect. We're pioneering safety with our strong legacy of leading brands like CISA®, Interflex®, LCN®, Schlage®, SimonsVoss® and Von Duprin®. Our comprehensive portfolio of hardware, software and electronic solutions is sold around the world and spans residential and commercial locks, door closer and exit devices, steel doors and frames, access control and workforce productivity systems. Allegion had $3.8 billion in revenue in 2024. For more, visit Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including, but not limited to, the company's ability to successfully integrate the acquisition, achieve anticipated strategic and financial benefits from the acquisition, and statements regarding the company's 2024 and future financial performance, the company's business plans and strategy, the company's growth strategy, the company's capital allocation strategy, and the performance of the markets in which the company operates. These forward-looking statements generally are identified by the words 'believe,' 'aim,' 'project,' 'expect,' 'anticipate,' 'estimate,' 'forecast,' 'outlook,' 'intend,' 'strategy,' 'future,' 'opportunity,' 'plan,' 'may,' 'should,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result' or the negative thereof or variations thereon or similar expressions generally intended to identify forward-looking statements. Forward-looking statements may relate to such matters as projections of revenue, margins, expenses, tax rate and provisions, earnings, cash flows, benefit obligations, dividends, share purchases or other financial items; any statements of the plans, strategies and objectives of management for future operations, including those relating to any statements concerning expected development, performance or market share relating to our products and services; any statements regarding future economic conditions or our performance; any statements regarding pending investigations, claims or disputes; any statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. Undue reliance should not be placed on any forward-looking statements, as these statements are based on the company's currently available information and our current assumptions, expectations and projections about future events. They are subject to future events, risks and uncertainties - many of which are beyond the company's control - as well as potentially inaccurate assumptions, that could cause actual results to differ materially from those in the forward-looking statements. Important factors and other risks that may affect the company's business or that could cause actual results to differ materially are included in filings the company makes with the Securities and Exchange Commission from time to time, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q and in its other SEC filings. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions. The company undertakes no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Yahoo
08-07-2025
- Yahoo
OTC Markets Group Welcomes Vaxart, Inc. to OTCQX
NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company, has qualified to trade on the OTCQX® Best Market. Vaxart, Inc. previously traded on NASDAQ. Vaxart, Inc. begins trading today on OTCQX under the symbol 'VXRT.' U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on Trading on the OTCQX Market offers companies efficient, cost-effective access to the U.S. capital markets. Streamlined market requirements for OTCQX are designed to help companies lower the cost and complexity of being publicly traded, while providing transparent trading for their investors. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. 'We thank OTC Markets Group for welcoming us and appreciate our investors for their continued support' said Steven Lo, Vaxart CEO. 'We remain focused on making meaningful scientific progress in developing oral pill vaccines to potentially transform public health.' About Vaxart, is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists About OTC Markets Group Inc. OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™️ Basic Market and Pink Limited Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets. OTC Link ATS, OTC Link ECN, OTC Link NQB, and MOON ATS are each SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC. To learn more about how we create better informed and more efficient markets, Subscribe to the OTC Markets RSS Feed Media Contact:OTC Markets Group Inc., +1 (212) 896-4428, media@ in to access your portfolio